evaluate the pharmaceuticals and biotechnology company novo nordisk on glp-1's Why Is Outperforming Lilly Despite Having Inferior GLP-1 Products? New oral GLP-1 drugs could
Description
The medical community has been slow to acknowledge it
News from food industry suppliers
This unique regulatory situation is contributing to a more competitive market somewhat earlier than in the U.S
Truveta Research tracks GLP-1 RA prescribing through March 2026, showing accelerated anti-obesity use and a sharp rise in first-time semaglutide prescribing.
